Influenza
RSSArticles
-
Oseltamivir (Tamiflu®): Current Treatment Indications and Its Role in the Treatment/Prevention of Avian Influenza
Neuraminidase inhibitors are a class of antivirals that have activity against both influenza A and B viruses. Influenza neuraminidase cleaves terminal sialic acid residues and damages the receptors recognized by viral hemagglutinin, thereby facilitating release of virus from infected cells. In the presence of a neuraminidase inhibitor, release of virus from infected cells is impaired and the progeny viruses that are freed clump together, as sialic acid has not been cleaved. -
Clinical Briefs By Louis Kuritzky, MD
Dietary Phytoestrogens and Lung Cancer Risk; Effectiveness of Influenza Vaccine in the Elderly; Why Does Tadalafil Cause Back Pain? -
Secondary Prevention with Flu Vaccine
-
Infection guidelines reach beyond hospital
-
Scientific analysis can detect endemic TB
-
Hepatitis E: A Synopsis of Recent Publications and Presentations
-
Self-Use of Rapid Tests for Malaria Diagnosis by Tourists Poses Difficulties
-
Welcome to Jurassic Park: Reptile-Associated Salmonellosis
-
Pharmacology Update: Influenza Virus Vaccine Live, Intranasal (FluMist)
The FDA has approved the first nasally administered flu vaccine. This cold-adapted, temperature sensitive, attenuated, trivalent vaccine is manufactured by MedImmune Vaccine, Inc. and marketed by MedImmune and Wyeth under the name FluMist. The nasal flu vaccine should be available this fall.